Utility of Fluorescence In Situ Hybridization Panel for Myelodysplastic Syndrome in Evaluation of Cytopenia in a Pediatric Hospital: A 5-Year Retrospective Review and Utilization Management

被引：0

作者：

Bunting, Cynthia T. ^{[1
]}

Senior, Tal ^{[2
]}

Susson, Yehuda ^{[2
]}

Rivera, Alethia ^{[3
]}

Saxe, Debra ^{[4
]}

Bunting, Silvia T. ^{[3
,4
]}

机构：

[1] Emory Univ, Atlanta, GA 30322 USA

[2] Childrens Healthcare Atlanta, Business Intelligence, Atlanta, GA USA

[3] Childrens Healthcare Atlanta, Dept Pathol, Atlanta, GA 30329 USA

[4] Emory Univ, Sch Med, Dept Pathol, Atlanta, GA 30322 USA

来源：

LABORATORY MEDICINE | 2017年 / 48卷 / 03期

关键词：

chromosome analysis; cytopenia; utility; fluoresence in situ hybridiation; myelodysplastic syndrome; BONE-MARROW; CYTOGENETICS; DIAGNOSIS; FISH; LEUKEMIA;

D O I：

10.1093/labmed/lmx047

中图分类号：

R446 [实验室诊断]; R-33 [实验医学、医学实验];

学科分类号：

1001 ;

摘要：

Background: MDS FISH was routinely ordered together with chromosome analysis for patients with cytopenia in our hospital. The utility of MDS FISH in the pediatric population is unknown. Objective: To analyze the utility of fluorescence in situ hybridization panel for myelodysplastic syndrome (MDS FISH) in the management of patients with cytopenia. Methods: We performed a retrospective review over a 5-year period, from 2009 to 2014 to determine whether chromosome analysis (CA) plus MDS FISH added useful information compared to chromosome analysis alone. Both CA and MDS FISH were performed on 253 bone marrow biopsies from 182 patients. Results: CA was highly correlated with MDS FISH (P < .0001) and detected all of the abnormalities seen by MDS FISH in 93.7% of the cases. CA is less expensive and detects additional chromosomal abnormalities not tested in the myelodysplastic syndrome panel. We propose MDS FISH should be ordered when CA fails to give adequate results.

引用

页码：266 / 270

页数：5